A Phase 1 interventional study of Apixaban in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-20.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy subjects
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
Drug: Apixaban
Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
Drug: Apixaban
Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
Drug: Apixaban
Also known as: BMS-562247
Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban
Samples of plasma from participants were obtained at the following times: 0 hour (h) and post dose at 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h. Apixaban was assayed using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method during the period of known analyte stability. Maximum observed plasma concentration (Cmax) was measured in nanograms per milliliter (ng/mL).
Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Death
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Day 1 to Day 12
Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
Samples of plasma from participants were obtained at the following times: 0 hour (h), 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. Maximum observed plasma concentration (Tmax) was measured in hours (h).
Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).
Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-INF) was measured in ng\*h/mL.
Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Mean Plasma Elimination Half-Life (T-HALF) of Apixaban
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. T-HALF was measured in hours (h).
Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Number of Participants With Clinically Significant Electrocardiogram, Vital Sign, or Physical Examination Findings
12-lead electrocardiograms (ECGs) and Vital Signs were performed at Screening, and Day 1 of Periods 1, 2 and 3 (pre-dose and prior to NGT placement, if done). Vital signs and ECGs were also performed on Day 4 of Period 3, prior to discharge from the study. Vital signs included body temperature, respiratory rate, seated blood pressure and heart rate. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes. Participants had physical examinations on Period 1, Day 1 (pre-dose) and Day 4 of Period 3, prior to study discharge.
Time frame: Screening, Day 1 of Periods, 1, 2, and 3, and Day 4 of Period 3
Number of Participants With Marked Abnormality in Hematology, Chemistry and Urinalysis Laboratory Tests
Participants were required to fast for at least 10 hours prior to the collection of specimens for clinical laboratory tests. Tests were performed at Screening, Day -1, and Day 4 of each period 1 - 3. Leukocyte criteria: Lower limits of normal (LLN), upper limits of normal (ULN), pre-treatment (preRX). Low Leukocytes: if value \< 0.9\*LLN, or if preRX \< LLN then use \< 0.85\* preRX. High lymphocytes: if value \> 7.500 10\^3 cells/ µL. Low neutrophils plus bands: if value \<= 1.500 10\^3 cells/µL. High creatine kinase: if value \> 1.5\* ULN. Blood in urine: if value \>= 2 plus, or if preRX \>= 1 plus then use \>= 2\*preRX.
Time frame: Screening, Day -1, Day 4 of Periods, 1, 2, and 3
Participants were admitted to the clinical facility on the evening prior to dosing (Day -1) and remained confined to the clinic for the duration of study.
| Milestone | Treatment A, Then Treatment B, Then Treatment C | Treatment A, Then Treatment C, Then Treatment B | Treatment B, Then Treatment A, Then Treatment C | Treatment B, Then Treatment C, Then Treatment A | Treatment C, Then Treatment A, Then Treatment B | Treatment C, Then Treatment B, Then Treatment A |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 3 | 4 | 3 |
| Completed | 4 | 3 | 4 | 3 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| participants | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Discontinuation Due to AE | 0 | 0 | 0 |
| SAE | 0 | 0 | 0 |
| Death | 0 | 0 | 0 |
| Adverse Events | 2 | 4 | 3 |
Samples of plasma from participants were obtained at the following times: 0 hour (h) and post dose at 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h. Apixaban was assayed using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method during the period of known analyte stability. Maximum observed plasma concentration (Cmax) was measured in nanograms per milliliter (ng/mL).
| ng/mL | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban | 190.873 (176.032 to 206.965) | 181.862 (162.834 to 203.112) | 153.693 (140.686 to 167.904) |
Samples of plasma from participants were obtained at the following times: 0 hour (h), 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. Maximum observed plasma concentration (Tmax) was measured in hours (h).
| h | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban | 0.517 (0.48 to 2.00) | 1.000 (0.30 to 2.00) | 1.00 (0.48 to 2.00) |
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).
| ng*h/mL | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban | 1269.784 (1140.000 to 1414.343) | 1226.339 (1064.999 to 1412.121) | 1166.572 (1031.549 to 1319.268) |
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-INF) was measured in ng\*h/mL.
| ng*h/mL | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban | 1292.775 (1161.691 to 1438.650) | 1250.913 (1088.380 to 1437.718) | 1192.387 (1056.600 to 1345.624) |
Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. T-HALF was measured in hours (h).
| h | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| Mean Plasma Elimination Half-Life (T-HALF) of Apixaban | 10.5 ± 4.2 | 10.4 ± 4.5 | 10.6 ± 3.8 |
12-lead electrocardiograms (ECGs) and Vital Signs were performed at Screening, and Day 1 of Periods 1, 2 and 3 (pre-dose and prior to NGT placement, if done). Vital signs and ECGs were also performed on Day 4 of Period 3, prior to discharge from the study. Vital signs included body temperature, respiratory rate, seated blood pressure and heart rate. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes. Participants had physical examinations on Period 1, Day 1 (pre-dose) and Day 4 of Period 3, prior to study discharge.
| participants | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| ECG | 0 | 0 | 0 |
| Vital Signs | 0 | 0 | 0 |
| Physical Examination | 0 | 0 | 0 |
Participants were required to fast for at least 10 hours prior to the collection of specimens for clinical laboratory tests. Tests were performed at Screening, Day -1, and Day 4 of each period 1 - 3. Leukocyte criteria: Lower limits of normal (LLN), upper limits of normal (ULN), pre-treatment (preRX). Low Leukocytes: if value \< 0.9\*LLN, or if preRX \< LLN then use \< 0.85\* preRX. High lymphocytes: if value \> 7.500 10\^3 cells/ µL. Low neutrophils plus bands: if value \<= 1.500 10\^3 cells/µL. High creatine kinase: if value \> 1.5\* ULN. Blood in urine: if value \>= 2 plus, or if preRX \>= 1 plus then use \>= 2\*preRX.
| participants | 5mg Apixaban |
|---|---|
| Low Leukocytes | 1 |
| High Lymphocytes | 1 |
| Low Neutrophils plus bands | 5 |
| High Creatine Kinase | 1 |
| Blood in Urine | 1 |
Collected over Day 1 to Day 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5mg Apixaban Via Oral Syringe (A) | — | 0/21 (0%) | 2/21 (9.5%) |
| 5mg Apixaban Via NGT Followed by D5W (B) | — | 0/21 (0%) | 4/21 (19%) |
| 5 mg Apixaban Via NGT Followed by Infant Formula (C) | — | 0/21 (0%) | 3/21 (14.3%) |
| Event | 5mg Apixaban Via Oral Syringe (A) | 5mg Apixaban Via NGT Followed by D5W (B) | 5 mg Apixaban Via NGT Followed by Infant Formula (C) |
|---|---|---|---|
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/21 | 0/21 | 1/21 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 0/21 | 1/21 | 0/21 |
| Abdominal PainGastrointestinal disorders | 1/21 | 1/21 | 0/21 |
| HeadacheNervous system disorders | 1/21 | 1/21 | 0/21 |
| Eyelid OedemaEye disorders | 0/21 | 1/21 | 0/21 |
| Arthropod biteInjury, poisoning and procedural complications | 0/21 | 0/21 | 1/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/21 | 0/21 | 1/21 |
| DysmenorrhoeaReproductive system and breast disorders | 0/21 | 1/21 | 0/21 |
All participants who received study drug were analyzed.
| Age, Continuous(years) | 5mg Apixaban |
|---|---|
| Mean | 33 ± 6.7 |
| Sex: Female, Male(Participants) | 5mg Apixaban |
|---|---|
| Female | 8 |
| Male | 13 |
| Region of Enrollment(participants) | 5mg Apixaban |
|---|---|
| United States | 21 |
The record gives a start of Jul 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban